Almirall (BATS-CHIXE:ALME) - Cotización, noticias y análisis

Resumen de acción ALME

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

Acerca de la empresa

ALME fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	4/6
Past Performance	2/6
Financial Health	6/6
Dividends	1/6

Recompensas

Cotiza un 64.7% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 49.36%

Análisis de riesgos

Acciones altamente ilíquidas

Los accionistas han sido diluidos en el último año

Competidores de Almirall, S.A.

Indivior

LSE:INDV

UK£2.0b

Hikma Pharmaceuticals

LSE:HIK

UK£4.3b

Dechra Pharmaceuticals

LSE:DPH

UK£4.4b

HUTCHMED (China)

AIM:HCM

UK£2.6b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Almirall
Historical stock prices
Current Share Price	€8.54
52 Week High	€9.31
52 Week Low	€7.87
Beta	0.36
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	-23.78%
5 Year Change	-43.22%
Change since IPO	26.33%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	ALME	GB Pharmaceuticals	Mercado GB
7D	0%	5.5%	1.7%
1Y	n/a	5.6%	1.4%

Rentabilidad vs. Industria: Datos insuficientes para determinar los resultados de ALME en comparación con el sector UK Pharmaceuticals .

Rentabilidad vs. Mercado: Datos insuficientes para determinar el rendimiento de ALME frente al mercado UK.

Volatilidad de los precios

Is ALME's price volatile compared to industry and market?
ALME volatility
ALME Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.1%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.3%
10% least volatile stocks in GB Market	2.7%

Precio estable de las acciones: ALME no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de ALME en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1943	1,876	Carlos Gallardo Piqué	www.almirall.com

Resumen de fundamentos de Almirall, S.A.

¿Cómo se comparan los beneficios e ingresos de Almirall con su capitalización de mercado?
Estadísticas fundamentales de ALME
Capitalización bursátil	€1.83b
Beneficios(TTM)	€6.98m
Ingresos (TTM)	€907.01m

262.5x

Ratio precio-beneficio (PE)

2.0x

Ratio precio-ventas (PS)

¿Está ALME sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ALME
Ingresos	€907.01m
Coste de los ingresos	€227.28m
Beneficio bruto	€679.73m
Otros gastos	€672.75m
Beneficios	€6.98m

Últimos beneficios comunicados

Sep 30, 2023

Próxima fecha de beneficios

Feb 19, 2024

Beneficios por acción (BPA)	0.033
Margen bruto	74.94%
Margen de beneficio neto	0.77%
Ratio deuda/patrimonio	23.2%

¿Cómo se ha desempeñado ALME a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

2.1%

Rentabilidad actual por dividendo

-301%

Ratio de pagos

Resumen de acción ALME

Recompensas

Análisis de riesgos

Competidores de Almirall, S.A.

LSE:INDV

UK£2.0b

LSE:HIK

UK£4.3b

LSE:DPH

UK£4.4b

AIM:HCM

UK£2.6b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Almirall, S.A., Annual General Meeting, May 10, 2024

Almirall, S.A. Provides Earnings Guidance for the Year 2024

Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases

Almirall, S.A. Receives European Commission Approval of EBGLYSS(R) (lebrikizumab) for Moderate to-Severe Atopic Dermatitis

Third quarter 2023 earnings released: EPS: €0.008 (vs €0.089 loss in 3Q 2022)

Almirall, S.A. Revises Earnings Guidance for the Year 2023

Recent updates

Almirall, S.A., Annual General Meeting, May 10, 2024

Almirall, S.A. Provides Earnings Guidance for the Year 2024

Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases

Almirall, S.A. Receives European Commission Approval of EBGLYSS(R) (lebrikizumab) for Moderate to-Severe Atopic Dermatitis

Third quarter 2023 earnings released: EPS: €0.008 (vs €0.089 loss in 3Q 2022)

Almirall, S.A. Revises Earnings Guidance for the Year 2023

Almirall, S.A. to Report Fiscal Year 2023 Results on Feb 19, 2024

Almirall's Ilumetri (Tildrakizumab) Significantly Improves Wellbeing for Patients and Their Relatives in Moderate-To-Severe Plaque Psoriasis

Almirall, S.A. Reiterates Earnings Guidance for the Year 2023

Almirall Launches Nina, the First Series to Highlight the Major Impact of Psoriasis on Patient’s Wellbeing

Almirall, S.A. has completed a Follow-on Equity Offering in the amount of €199.999993 million.

First quarter 2023 earnings released

Almirall, S.A. Reiterates Earnings Guidance for the Year 2023

Full year 2022 earnings released: EPS: €0.02 (vs €0.23 loss in FY 2021)

Almirall, S.A., Annual General Meeting, May 05, 2023

Now 20% undervalued

Almirall, S.A. to Report Nine Months, 2023 Results on Nov 16, 2023

Almirall, S.A. Maintains Earnings Guidance for the Full Year of 2022

Almirall, S.A. Announces EMA Acceptance for Filing of Marketing Authorization Application (MAA) for Lebrikizumab in Atopic Dermatitis

Almirall, S.A. Announces the 31st EADV Congress the Results from TRIBUTE, an Interventional Phase IV Clinical Study

Almirall, S.A. Announces New Detailed Results from Phase 3 Monotherapy Studies in Atopic Dermatitis

Second quarter 2022 earnings released: EPS: €0.039 (vs €0.40 loss in 2Q 2021)

Insufficient new directors

Insufficient new directors

Almirall, S.A.(BME:ALM) dropped from Madrid Ibex 35 Index

Happify Health and Almirall, S.A. Go Live with Digital Solution to Support Psoriasis Patients

Almirall, S.A. Announces Topline Results from One-Year Analyses of the Efficacy and Safety of Lebrikizumab

Almirall, S.A. Announces Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Almirall, S.A. Announces Executive Changes

Almirall launches innovative Wynzora® CAL/BDP cream in Europe for the treatment of mild to moderate plaque psoriasis in adults including scalp

Almirall Announces Results for Atopic Dermatitis in Third Phase 3 Study

Almirall, S.A. Launches Klisyri (Tirbanibulin) for the Treatment of Actinic Keratosis in Europe

Almirall, S.A. Receives European Commission Approval of Klisyri® (Tirbanibulin)

Almirall and MC2 Therapeutics Announce Completion of Decentralized Procedure in Europe for the Topical Treatment of Mild to Moderate Psoriasis Vulgaris in Adults

Almirall Receives Positive CHMP Opinion for Klisyri®? (Tirbanibulin), an Innovative Topical Treatment for Actinic Keratosis

First quarter 2021 earnings released: EPS €0.17 (vs €0.28 in 1Q 2020)

Full year 2020 earnings released: EPS €0.42 (vs €0.61 in FY 2019)

Revenue misses expectations

Almirall U.S. Launches Klisyri® (tirbanibulin), a New, Innovative Topical Treatment for Actinic Keratosis

Almirall and MC2 Therapeutics Enters a License, Collaboration and Commercialization Agreement for European Rights to Wynzora® Cream for treatment of Plaque Psoriasis

Almirall, S.A. Announces New Publication in the British Journal of Dermatology of ILUMETRI

Almirall, S.A. Announces Executive Changes

Almirall and Happify Health Enter into Strategic Partnership to Develop Evidence-Supported Digital Therapeutics Solutions for Psoriasis Patients

New 90-day high: €12.00

Almirall, S.A. and Tyris Therapeutics Enter into Strategic Partnership to Develop Next Generation Gene Therapies

New 90-day high: €11.29

Almirall, S.A. Announces U.S. Food and Drug Administration Approval of Klisyri® (Tirbanibulin), A New Innovative Topical Treatment for Actinic Keratosis

Popit and Almirall Start Offering New Support Tool to Help Psoriasis Patients

Almirall, S.A. Announces Promotion of Pablo Alvarez as President of Almirall US

Almirall, S.A. Announces Resignation of Peter Guenter as Chief Executive Officer at the End of the Year

Almirall, S.A. Announces Full 5 Year Data Analysis from Two Phase III Clinical Studies, reSURFACE 1 and reSURFACE2 of ILUMETRI

Almirall, S.A. Announces Approval of the Reimbursed Price for Ilumetri® (Tildrakizumab) in France for the Treatment of Adult Patients with Severe Chronic Plaque Psoriasis

Almirall, S.A. and the University of Dundee Announce Multi-Target Research Collaboration to Develop Novel Targeted Protein Degraders Medicines

Neuraxpharm Italy SpA acquired Ansiolin Brand from Almirall, S.A. (BME:ALM).

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Almirall, S.A.